# Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)

> **NCT02245568** · PHASE3 · TERMINATED · sponsor: **TauRx Therapeutics Ltd** · enrollment: 913 (actual)

## Conditions studied

- Alzheimer's Disease
- Behavioral Variant Frontotemporal Dementia

## Interventions

- **DRUG:** LMTM

## Key facts

- **NCT ID:** NCT02245568
- **Lead sponsor:** TauRx Therapeutics Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-08
- **Primary completion:** 2017-05
- **Final completion:** 2017-05
- **Target enrollment:** 913 (ACTUAL)
- **Why stopped:** This study has been terminated for administrative reasons only.
- **Last updated:** 2023-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02245568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02245568, "Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02245568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*